Cost-effectiveness analysis of neoadjuvant docetaxel plus androgen deprivation therapy before radical prostatectomy in high-risk localized prostate cancer
Randomized trial evaluates cost-effectiveness of neoadjuvant chemohormonal therapy in high-risk localized prostate cancer, indicating strong economic viability.
Key Points
This study evaluates the economic efficacy of neoadjuvant chemohormonal therapy prior to radical prostatectomy for high-risk localized prostate cancer.
Constructed a partitioned survival model with three states: event-free survival, progressive disease, and death.
Utilized clinical efficacy data from the CALGB 90203 trial and local data for costs and utility values.
Calculated lifetime costs, quality-adjusted life-years, and incremental cost-effectiveness ratios using a 5% discount rate.
Neoadjuvant CHT provided an additional 1.08 QALYs at an incremental cost of $5,663, yielding an ICER of $5,238 per QALY.
Probabilistic sensitivity analysis showed a 96.40% probability that neoadjuvant CHT is cost-effective under the $41,859 WTP threshold.